Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

被引：3
|
作者：
Yue, D. [1 ]
Xu, S. [2 ]
Wang, Q. [3 ]
Li, X. [4 ]
Shen, Y. [5 ]
Zhao, H. [6 ]
Chen, C. [7 ]
Mao, W. [8 ]
Liu, W. [9 ]
Liu, J. [10 ]
Zhang, L. [11 ]
Ma, H. [12 ]
Li, Q. [13 ]
Yang, Y. [14 ]
Liu, Y. [15 ]
Chen, H. [16 ]
Wang, C. [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Canc Inst & Hosp, Tianjin, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, XiAn Hosp, Xian, Shaanxi, Peoples R China
[5] Qing Dao Univ, Hosp 1, Qingdao, Shandong, Peoples R China
[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[7] Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
[8] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[9] Jilin Univ, Bethune Hosp 1, Changchun, Jilin, Peoples R China
[10] Tumor Hosp Hebei Prov, Shijiazhuang, Hebei, Peoples R China
[11] Sun Yat Sen Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China
[12] Suzhou Univ, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
[13] Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
[14] Peking Univ, Canc Hosp, Beijing, Peoples R China
[15] Liaoning Canc Hosp, Shenyang, Tianjin, Peoples R China
[16] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Adjuvant therapy; Erlotinib; EGFR mutation;
D O I：
10.1016/j.jtho.2017.09.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 16.04
引用
收藏
页码：S1789 / S1789
页数：1
相关论文
共 50 条
  • [31] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [32] Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects
    Chuang, Jody C.
    Neal, Joel W.
    Niu, Xiao-Min
    Wakelee, Heather A.
    LUNG CANCER, 2015, 90 (01) : 1 - 7
  • [33] Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Fulton, Linnea E.
    Digumarthy, Subba R.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Sequist, Lecia V.
    ACADEMIC RADIOLOGY, 2016, 23 (03) : 329 - 336
  • [34] Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs
    Ye, J.
    Liu, J.
    Yang, Y.
    Lv, W.
    Xu, W.
    Xia, P.
    Wang, L.
    Zhu, L.
    Hu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S554 - S554
  • [35] HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non Small Cell Lung Cancer
    Hu, W.
    Mao, Z.
    Cheng, N.
    Huang, J.
    Tang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S563 - S564
  • [36] Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy?
    Patel, S.
    Rimner, A.
    Foster, A.
    Zhang, Z.
    Woo, K. M.
    Yu, H. A.
    Riely, G. J.
    Wu, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S643 - S643
  • [37] Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy?
    Patel, S.
    Rimner, A.
    Foster, A.
    Zhang, Z.
    Woo, K. M.
    Yu, H. A.
    Riely, G. J.
    Wu, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S45 - S46
  • [38] TUMOR RESPONSE AND TOXICITY IN NEO-ADJUVANT ERLOTINIB IN EARLY STAGE NSCLC PATIENTS
    Schaake, Eva E.
    Klomp, Houke M.
    Burgers, J. A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S387 - S388
  • [39] Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Chen, Dong
    Jin, Zixian
    Zhang, Jian
    Xu, Congcong
    Zhu, Kanghao
    Ruan, Yuhang
    Zhang, Bo
    Chen, Baofu
    Shen, Jianfei
    FRONTIERS IN SURGERY, 2021, 8
  • [40] Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
    Wang, Yuchen
    Ma, Xiaobo
    Ma, Kewei
    Chen, Xi
    He, Hua
    Zhao, Xiangye
    Fan, Mengge
    Xu, Yinghui
    FRONTIERS IN IMMUNOLOGY, 2025, 15
12345